Medicare expands home infusion therapy, opens door to nurse practitioners

What it does

This bill expands Medicare coverage for home infusion therapy by adding pharmacy services to the list of covered items, allowing nurse practitioners and physician assistants (not just doctors) to establish and oversee treatment plans, extending coverage to non-pump drugs like antibiotics and antivirals, and adjusting payment rates. Starting January 1, 2026, Medicare will pay for infusion therapy even when a supplier is not physically present in the home (at 50% of the normal rate), and will cover pharmacy preparation and coordination services alongside nursing care.

Why we flagged it

The bill's core function is to broaden Medicare reimbursement for home infusion therapy services, add eligible providers, and extend coverage to new drug categories. This is a straightforward healthcare access expansion, not a tax provision, deregulation, or narrow carve-out.

What the text implies

• The 50% payment reduction for remote administration (when supplier not physically present) may incentivize in-home visits even when clinically unnecessary, potentially increasing costs and patient burden.
• Expansion to non-pump drugs (antibiotics, antivirals) significantly broadens the addressable market for home infusion suppliers; financial beneficiaries may include home health agencies and specialty pharmacy companies.
• Nurse practitioner and physician assistant authority to establish care plans reduces physician gatekeeping but may create inconsistent clinical standards across providers with different training backgrounds.
• The 'transitional rule' (2026–2030) guaranteeing 5 hours of infusion payment per day may lock in higher reimbursement rates that persist after the transition period ends, creating a de facto permanent rate floor.

Who it affects

Patients gain expanded access to home-based infusion therapy with lower barriers to care (nurse practitioners and physician assistants can now oversee plans), broader drug coverage, and maintained payment for services even when suppliers are not physically present. The 50% payment reduction for remote administration may create some access friction, but the overall expansion of covered services and eligible providers increases patient choice and convenience.

Who stands to gain

• home infusion therapy suppliers
• specialty pharmacy companies
• home health agencies
• durable medical equipment providers

Named in the bill

Medicare, Social Security Act Section 1861, Social Security Act Section 1834, qualified home infusion therapy suppliers, nurse practitioners, physician assistants, US Pharmacopeia, HCPCS codes A4221, A4222, K0552

Where it stands

30 cosponsors: 18 Democrats, 12 Republicans.

• Mar 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 18, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

7 lobbying clients named this bill on 10 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,654,000 in lobbying spend. A filing names 33 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 86% of bills with at least one filing.

Vern Buchanan, the sponsor, reported $544,700 in PAC receipts in the 2026 cycle.

• American Association of Nurse Practitioners — $950,000 on 2 filings
• American Nurses Association — $270,000 on 1 filing
• National Home Infusion Association — $160,000 on 2 filings
• Premier, Inc. — $140,000 on 1 filing
• Option Care Enterprises, Inc. — $80,000 on 2 filings

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.